How many investments has LYFE Capital made?

LYFE Capital has 25 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.

What stage does LYFE Capital invest at?

LYFE Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is LYFE Capital located?

LYFE Capital is headquartered in Menlo Park, US.

Does LYFE Capital lead rounds?

LYFE Capital typically participates in rounds rather than leading them.

Who does LYFE Capital co-invest with?

LYFE Capital most often shares deals with B Capital Group, B4 Capital, LAV, among 12 tracked co-investors.

LYFE Capital

Venture capital

Menlo Park · Seed–Late Stage · 22 people tracked

Also known as LYFE CAPITAL GLOBAL PARTNER LIMITED · LYFE CAPITAL INVESTMENT MANAGEMENT (HONG KONG) LIMITED · LYFE CAPITAL INVESTMENT MANAGEMENT (SHANGHAI) CO., LTD. · LYFE CAPITAL INVESTMENT MANAGEMENT LIMITED · LYFE U.S LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into LYFE Capital

Paths you didn't know you had: your email and LinkedIn already hold routes to the LYFE Capital team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

LYFE Capital is a healthcare investment platform led by investment veterans and operators who have navigated multiple market cycles. Operating from five global offices in Asia and the United States, the firm targets critical healthcare supply chain assets, specialized product platforms, and next-generation R&D services. Its aim is to help these companies grow significant and resilient revenues by tapping into global mature markets.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices RoboticsSector AgnosticAsia-Pacific China Grand Cayman Japan Menlo Park North America Shanghai Singapore South Korea United States Wilmington

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Menlo Park, US

Leads rounds

Follows

Instruments

Equity

Founded

2015

AUM

$2B

VC funds

Tracked investments

Acquisitions

Team · 22 people

from the firm's website & public directories

Alan Wang· Managing Director· Singapore

Managing Director focused on MedTech investments across Asia and the U.S., with landmark deals including Kangji, EDGE, Noah, and Fong's Engineering. Previously worked in corporate strategy at Bristol Myers Squibb and as a healthcare consultant.

Frances Chovanec· Managing Director· New York Cityin

Managing Director focused on buyout strategies, bolt-on acquisitions, exits, and capital markets, with 20+ years in finance. Previously CFO of Kangji Medical and a banker at Morgan Stanley and Goldman Sachs; also worked at Fosun Group. Holds an MBA from Wharton.

Peter Lee· Managing Director· New Jerseyin

Managing Director with over 10 years of healthcare transaction and investment experience, developing thematic strategies. Previously a partner at Avant Bio and analyst at Casdin Capital. Holds a BA in Economics from University of Chicago.

Yao Li Ho· Managing Director· California and Tokyoin

Managing Director supporting U.S. operations and cross-border healthcare investments. Previously International Business Development Lead at Yangtze River Pharmaceutical Group and a consultant at ChinaBio. Holds an MBA from the Tsinghua/MIT Sloan program.

Gang Chen· General Partner

Ho Li Yao· General Partner

Jin Zhao· General Partner

Zhengkun Yu· General Partner

James Zhao· Founder and Partner· New Jerseyin

Founder and Partner who grew LYFE Capital into a transpacific healthcare investment platform with USD 2 billion in AUM. Previously built the Asia practice for Vivo Capital as Managing Partner and worked at Monitor Group. Holds an MBA from Olin Business School.

jzhao@lyfecapital.com

William Chen· Partner· Singaporein

Partner with expertise in Asian healthcare markets, focused on high-growth opportunities across China, Korea, and Southeast Asia. Previously seconded to IMEIK Technology and a consultant at L.E.K. Consulting. Holds an MBA from Kellogg.

Derek Yuan· Partner· San Francisco Bay Area

Partner with over 15 years in life sciences research and investment, working with US and Asian teams on therapeutic investments and post-deal management. Previously an Equity Research Associate at Credit Suisse and consultant at L.E.K. Holds a Ph.D. from Rockefeller University.

dyuan@lyfecapital.com

Jack Chen· Partner· Singaporein

Partner with 18 years in healthcare investment and strategic consulting, focused on talent development and portfolio management. Previously a Principal at VIVO Capital and consultant at L.E.K. Consulting. Holds an MBA from Kellogg.

Sameer Rohatgi· Partner· San Diegoin

Partner since 2018 who built the US-based team, with 25+ years of global operating experience in life science tools, diagnostics, and clinical research. Previously headed international corporate and business development at Illumina and was a founding executive at Helixis.

srohatgi@lyfecapital.com

Alvin Koh· Investment Principal and Senior Director, APAC Business Development· Singaporein

Investment Principal and Senior Director of APAC Business Development. Previously led Illumina's APJ business development and lifecycle management functions over 14 years. Holds an MBA from University of Chicago Booth.

Jing Xu· Principal· Singapore, Singaporein

Principal focused on Asian biotech and pharmaceutical investments, deal sourcing, and value creation. Led investments in MediLink, Profound Bio, and Sciwind. Previously held senior roles at Amgen and WuXi AppTec; holds a Ph.D. from Northeastern University.

Yoshitaka Nagai· Principal· Japanin

Principal focused on sourcing and executing healthcare investments in Japan across pharma, med-tech, and pharma services. Previously spent 12 years in Nomura Securities' healthcare investment banking. Holds economics degrees from University of Tokyo and Boston University.

Fong Ming Koh· Principal· Singaporein

Principal focused on biopharma opportunities across Asia, including therapeutic assets and CRO/CDMO buyouts. Previously Head of Life Sciences at Heritas Capital. Holds a Ph.D. in Biomedical Sciences from UCSF.

fkoh@lyfecapital.com

David Liu· Director of Investor Relations· Singapore

Director of Investor Relations leading firm strategy, fundraising, and internal portfolio review. Previously grew a medical aesthetic clinic chain and founded a media company. Holds an MBA from Columbia Business School.

Laura Lu· Chief Legal Officer· New Jerseyin

Chief Legal Officer and ESG coordinator with over 30 years of legal experience in fund formation, transactions, and compliance. Previously Legal Director at MSD China and Senior Legal Counsel at Siemens China.

Roy Xu· Chief Financial Officer· Shanghai and Californiain

Chief Financial Officer with over 20 years of financial expertise, managing the firm's finance operations, fundraising, and budgeting. Previously VP at GP Capital and worked at PwC. Holds a bachelor's degree from Fudan University and is a CPA.

Vivien Li· Director of Business Development

Director of Business Development supporting value creation for portfolio companies and post-deal management. Previously founded a healthcare company and was a founding partner of a China-focused healthcare VC firm. Holds an MBA from CUHK.

LYFE Transpacific Engine Limited· Executive Officer

Founder mafia

2 people who came through LYFE Capital went on to found or lead other companies.

Jamin LiuInvestment Analyst InternFounded Monte Keting ChuPartnerFounded Bluejaytx

What they invest in

from 14 of 25 portfolio companies

Biotech ×12Healthtech ×10Medical Devices ×5Deep Tech ×4Digital Health ×3Advanced Manufacturing ×2Wellness & Fitness ×2AI & Machine Learning ×1

HQs:United States×6China×2Taiwan×1

Investments · 25 tracked

founders shown can be your intro path

By year:2025 · 1 2024 · 1 2022 · 1 2021 · 1 2020 · 1 2018 · 16 dated

Cytotronicscytotronics.com inMar 2024✓ verifiedacquired by Axion BioSystems · Jan 2026

Cytotronics develops Pixel, a semiconductor-to-live-cell interface platform that measures cell viability, morphology, electrophysiology, and metabolism at single-cell resolution across any cell type or 3D organoid system.

BiotechDeep TechSemiconductorsBoston, US

Jeffrey Abbott(Co-Founder & CEO)in Duane Sword(Co-Founder & CBO)inDonhee Ham(Scientific Co-Founder)inHongkun Park(Scientific Co-Founder)Vince (Wenxuan) Wu(Founder)inWenxuan Wu(Executive Officer, Director)

Co-investorsAnzu Partners Bantam Group Draper Associates BoxOne Ventures

Guokangguokang.com✓ verified

Guokang is a Chinese health management company providing private-doctor and corporate health management services, primarily to executives and directors of large enterprises, along with health insurance brokerage and an online health-management SaaS platform.

Digital HealthHealthtechSaaSWellness & FitnessShenzhen, CN

杨华山(Chairman & CEO)Yang Huashan(Chairman & CEO)

Co-investorsQiming Venture Partners

Iecureiecure.com✓ verified

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.

BiotechHealthtechMedical Devices

James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)inPaul Firuta(COO)inAlex Monteith(Chief Business Officer)David Garrett(CFO)in Gabriel M. Cohn(Chief Medical Officer)in

Co-investorsOrbiMed Versant Ventures

Aspen Neuroscienceaspenneuroscience.com in 𝕏May 2022

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARCH Venture Partners Lifeforce Capital OrbiMed Domain Associates EDB Investments Section 32 +10 more

Bora Pharmaceuticalsbora-corp.com in

Bora Pharmaceuticals is a pharmaceutical services company offering CDMO (contract development and manufacturing) for both small molecule and large molecule/biologics products, alongside its own drug development focused on specialty pharma and rare diseases.

Advanced ManufacturingBiotechHealthtech

Bobby Sheng(Founder)in

HiFiBiO Therapeuticshifibio.com in 𝕏May 2018 · $37.5M

HiFiBiO Therapeutics develops immunotherapies for patients with high unmet medical needs, using its Drug Intelligence Science (DIS) platform that combines single cell technology with AI/ML analytics.

AI & Machine LearningBiotechHealthtech

Liang Schweizer(Founder)in

Co-investorsB Capital Group B4 Capital Trinity Innovation Bioventure Singapore IDG Capital Legend Capital Nest.Bio Ventures +1 more

IMEIK Technologyimeikglobal.com

An enterprise that develops and commercializes biomedical materials and biopharmaceutical products, including Class III and Class II medical devices, dermal fillers, facial threads, and proteins/peptides for medical aesthetics, dermatology, surgery, metabolic disease, and professional skincare.

BiotechHealthtechMedical DevicesWellness & FitnessBeijing, CN

Molecular Assembliesmolecularassemblies.comJul 2020

Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.

BiotechDeep TechNew MaterialsSan Diego, US

J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)Bill Efcavitch(Founder)Curt Becker(Founder)

BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)

Co-investors11.2 Capital DCVC (Data Collective)iSelect Fund Keshif Ventures Rising Tide Alexandria +2 more

Neurona Therapeuticsneuronatherapeutics.com inApr 2025 · $102M

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)in Catherine Priest(Chief Development Officer)in Gautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Co-investorsBerkeley Frontier Iaso Ventures The Column Group Viking Global Ysios Capital Alexandria +8 more

Noahmednoahmed.com in 𝕏

Noah Medical develops robotic and software solutions for diagnostic bronchoscopy procedures, designed to enable earlier lung cancer diagnosis with improved accuracy.

HealthtechMedical DevicesRoboticsSilicon Valley, US

Jian Zhang(Founder & CEO)Enrique Romo inFrank Grilloin

Co-investors1955 Capital China Growth Capital Prosperity7 Ventures ShangBay Capital LLC

Nucleixnucleix.com in 𝕏Apr 2021 · $55M

Nucleix is a healthcare company developing diagnostic technology based on DNA/nucleic acid analysis for cancer detection.

BiotechDigital HealthHealthtechMedical Devices

Eli Frydman(President EMEA)

Co-investorsGefen Capital OrbiMed RA Capital Aurum Ventures MKI BlackRock Lilly Asia Ventures +1 more

Profound Bioprofoundbio.com

Acquired by Genmab in April 2024.

Co-investorsB Capital Group B4 Capital HongShan Capital Group LAV LifeSci Venture Partners Lilly Asia Ventures +2 more

Sciwindsciwindbio.com

Sciwind Biosciences is a commercial-stage biopharmaceutical company that discovers, develops, and delivers therapeutics focused on metabolic and weight management conditions, serving patients globally.

BiotechHealthtech

ST Pharmstpharm.co.kr in

ST Pharm is a contract development and manufacturing organization (CDMO) producing active pharmaceutical ingredients, with a focus on gene therapy and nucleic acid technologies spanning oligonucleotides to xRNA.

Advanced ManufacturingBiotechHealthtech

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

BrightechChemLexCleveland DiagnosticsEDGEEdge MedicalFong's EngineeringJeisis MedicalKali TherapeuticsKangji MedicalMediLinkNoah

Exits · 1

1 acquisitions

Cytotronicsacq. by Axion BioSystems

Portfolio news

latest coverage across their companies

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Aspen Neuroscience · prnewswire.com · Nov 20, 2025

Molecular Assemblies, Inc. Secures $83M to Fuel the Fully Enzymatic DNA Synthesis Revolution | SignalBase

Molecular Assemblies · leadsontrees.com · Apr 9, 2025

Frequently asked questions

How many investments has LYFE Capital made?: LYFE Capital has 25 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.
What stage does LYFE Capital invest at?: LYFE Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does LYFE Capital focus on?: LYFE Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices, Robotics, Sector Agnostic.
Where is LYFE Capital located?: LYFE Capital is headquartered in Menlo Park, US.
Does LYFE Capital lead rounds?: LYFE Capital typically participates in rounds rather than leading them.
Who does LYFE Capital co-invest with?: LYFE Capital most often shares deals with B Capital Group, B4 Capital, LAV, among 12 tracked co-investors.

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

$100K – $10M

Khosla Ventures

Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.

$100K – $20M

EQT Life Sciences

EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.

$11M – $66M